Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVACFLU-S in Healthy Adults
NCT02598089Phase 1Completed
- Sponsor
- Institute of Vaccines and Medical Biologicals
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IVACFLU-S in influenza (2 arms), sponsored by Institute of Vaccines and Medical Biologicals. Primary endpoints: Number of Participants With Immediate Adverse Events at 30 minutes, Number and Percentage of Participants Reporting Solicited Local Reactogenicity at 7 days and 3 more. Started Nov 2015; status: completed.
02
Drugs
IVACFLU-S
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02598089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598089.